Patents by Inventor Mohd Zainuddin
Mohd Zainuddin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220281815Abstract: The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.Type: ApplicationFiled: April 29, 2022Publication date: September 8, 2022Inventors: Sridharan RAJAGOPAL, Mahanandeesha S. HALLUR, Purushottam DEWANG, Kannan MURUGAN, Durga Prasanna KUMAR C.H., Pravin IYER, Chandrika MULAKALA, Dhanalakshmi SIVANANDHAN, Sreekala NAIR, Mohd ZAINUDDIN, Subramanyam Janardhan TANTRY, Chandru GAJENDRAN, Sriram RAJAGOPAL
-
Patent number: 11352322Abstract: The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.Type: GrantFiled: May 8, 2017Date of Patent: June 7, 2022Assignee: Jubilant Epicore LLCInventors: Sridharan Rajagopal, Mahanandeesha S. Hallur, Purushottam Dewang, Kannan Murugan, Durga Prasanna Kumar C. H., Pravin Iyer, Chandrika Mulakala, Dhanalakshmi Sivanandhan, Sreekala Nair, Mohd Zainuddin, Subramanyam Janardhan Tantry, Chandru Gajendran, Sriram Rajagopal
-
Publication number: 20200308110Abstract: The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.Type: ApplicationFiled: May 8, 2017Publication date: October 1, 2020Inventors: Sridharan RAJAGOPAL, Mahanandeesha S. HALLUR, Purushottam DEWANG, Kannan MURUGAN, Durga Prasanna KUMAR C.H., Pravin IYER, Chandrika MULAKALA, Dhanalakshmi SIVANANDHAN, Sreekala NAIR, Mohd ZAINUDDIN, Subramanyam Janardhan TANTRY, Chandru GAJENDRAN, Sriram RAJAGOPAL
-
Patent number: 10471051Abstract: The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R1 to R8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: GrantFiled: September 1, 2017Date of Patent: November 12, 2019Assignee: Asana BioSciences, LLCInventors: Aranapakam M. Venkatesan, Scott K. Thompson, Roger A. Smith, Sanjeeva P. Reddy, Raghava Reddy Kethiri, Purushottam M. Dewang, Gurulingappa Hallur, Chandrika Mulakala, Ramesh Mullangi, Mohd Zainuddin
-
Publication number: 20180230098Abstract: The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).Type: ApplicationFiled: April 13, 2018Publication date: August 16, 2018Applicant: Norgine B.V.Inventors: Rajagopal Bakthavatchalam, Manas Kumar Basu, Ajit Kumar Behera, Chandregowda Venkateshappa, Christopher Alexander Hewson, Sanjay Venkatachalapathi Kadnur, Sarkis Barret Kalindjian, Bheemashankar Kulkarni, Rohit Saxena, Juluri Suresh, Vellarkad Viswanathan, Mohd Zainuddin, Akila Parvathy Dharshinis, Rajenda Kristam
-
Patent number: 9969687Abstract: The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).Type: GrantFiled: December 22, 2014Date of Patent: May 15, 2018Assignee: Norgine B.V.Inventors: Rajagopal Bakthavatchalam, Manas Kumar Basu, Ajit Kumar Behera, Chandregowda Venkateshappa, Christopher Alexander Hewson, Sanjay Venkatachalapathi Kadnur, Sarkis Barret Kalindjian, Bheemashankar Kulkarni, Rohit Saxena, Juluri Suresh, Vellarkad Viswanathan, Mohd Zainuddin, Akila Parvathy Dharshinis, Rajenda Kristam
-
Patent number: 9896445Abstract: The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R1 to R8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: GrantFiled: June 15, 2016Date of Patent: February 20, 2018Assignee: Ansana BioSciences, LLCInventors: Aranapakam M. Venkatesan, Scott K. Thompson, Roger A. Smith, Sanjeeva P. Reddy, Raghava Reddy Kethiri, Purushottam M. Dewang, Gurulingappa Hallur, Chandrika Mulakala, Ramesh Mullangi, Mohd Zainuddin
-
Publication number: 20170362216Abstract: The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R1 to R8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: ApplicationFiled: September 1, 2017Publication date: December 21, 2017Inventors: Aranapakam M. Venkatesan, Scott K. Thompson, Roger A. Smith, Sanjeeva P. Reddy, Raghava Reddy Kethiri, Purushottam M. Dewang, Gurulingappa Hallur, Chandrika Mulakala, Ramesh Mullangi, Mohd Zainuddin
-
Publication number: 20170002011Abstract: The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).Type: ApplicationFiled: December 22, 2014Publication date: January 5, 2017Applicant: Norgine B.V.Inventors: Rajagopal Bakthavatchalam, Manas Kumar Basu, Ajit Kumar Behera, Chandregowda Venkateshappa, Christopher Alexander Hewson, Sanjay Venkatachalapathi Kadnur, Sarkis Barret Kalindjian, Bheemashankar Kulkarni, Rohit Saxena, Juluri Suresh, Vellarkad Viswanathan, Mohd Zainuddin, Akila Parvathy Dharshinis, Rajenda Kristam
-
Publication number: 20170001959Abstract: The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).Type: ApplicationFiled: December 22, 2014Publication date: January 5, 2017Applicant: Norgine B.V.Inventors: Rajagopal Bakthavatchalam, Manas Kumar Basu, Ajit Kumar Behera, Chandregowda Venkateshappa, Christopher Alexander Hewson, Sanjay Venkatachalapathi Kadnur, Sarkis Barret Kalindjian, Bheemashankar Kulkarni, Rohit Saxena, Juluri Suresh, Vellarkad Viswanathan, Mohd Zainuddin, Akila Parvathy Dharshinis, Rajenda Kristam